Clinical characteristics of patients treated with rapid infusion rituximab in the safety analysis in combination with corticosteroid-containing chemotherapy and as maintenance therapy following induction therapy
| . | Rituximab and steroid-containing chemotherapy . | Rituximab maintenance therapy . |
|---|---|---|
| No. patients | 150 | 56 |
| Median age, y (range) | 60 (19-92) | 58 (35-81) |
| Chemotherapy, % | ||
| CHOP | 81 | — |
| CVP | 16 | — |
| Other | 3 | — |
| Histology, % | ||
| DLBCL | 58 | — |
| Follicular | 23 | 66 |
| Other | 19 | 34 |
| No. of infusions | 473 | 92 |
| Median no. of rapid infusions | 3 | 2 |
| . | Rituximab and steroid-containing chemotherapy . | Rituximab maintenance therapy . |
|---|---|---|
| No. patients | 150 | 56 |
| Median age, y (range) | 60 (19-92) | 58 (35-81) |
| Chemotherapy, % | ||
| CHOP | 81 | — |
| CVP | 16 | — |
| Other | 3 | — |
| Histology, % | ||
| DLBCL | 58 | — |
| Follicular | 23 | 66 |
| Other | 19 | 34 |
| No. of infusions | 473 | 92 |
| Median no. of rapid infusions | 3 | 2 |
CHOP indicates cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; DLBCL, diffuse large B-cell lymphoma; and —, not applicable.